Article
High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome.
Leukemia - 1 Jan 2003
Feller N, Schuurhuis G J, van der Pol M A, Westra G, Weijers G W D, van Stijn A, Huijgens P C, Ossenkoppele G J
Abstract excerpt
In this study, a high CD34% in autologous peripheral blood stem cell (PBSC) products from 71 AML patients was associated directly with a high relapse rate (P = 0.006) and inversely with disease-free survival (P = 0.003), irrespective whether patients were transplanted or not. The relapse rate at 12 months was 67% in a group with >0.8% CD34+ cells and 34% in a group with < or = 0.8% CD34+ cells. Although the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.